Two Risk Factors, and Neither Cancels the Other Out
A single patient, presenting with acute epididymitis and two independently plausible explanations. The disagreement isn't about which exposure is real — both are — it's about whether the guideline's risk-based framework was ever meant to force a choice between two genuine risk factors present at once.
Marcus T., a 36-year-old man who drives for a rideshare service ten hours a day in a car that has become, by his own description, "basically my office," came in for a hematuria workup six weeks ago that included a diagnostic cystoscopy — routine, unremarkable, and resolved without incident once a small, benign bladder polyp was fulgurated during the same visit. He has no chronic medical conditions, takes no regular medications, and had never needed a urologic procedure of any kind before this year. Today he presents with a day of worsening left-sided scrotal pain and swelling, tender epididymis on exam, no fever, no urethral discharge visible on inspection. His initial history is straightforward: married two years, monogamous. It is only midway through the visit, after the clinician asks a second, more specific question about any recent change in that pattern, that he mentions — visibly uncomfortable — a single encounter outside the relationship about three weeks ago, protected, but real.
The CDC's 2021 STI treatment guidelines moved epididymitis management away from a strict age cutoff and toward an exposure- and risk-based framework, and they name three regimens rather than two. Chlamydia or gonorrhea alone: ceftriaxone plus doxycycline. Enteric organisms alone — classically after urologic instrumentation such as cystoscopy, prostate biopsy, or catheterization: levofloxacin. And, for men judged at risk of both at once, a third regimen that is not the first two added together but a substitution — ceftriaxone plus levofloxacin, doxycycline dropped, because levofloxacin already covers chlamydia. Marcus carries both exposures: a sexual encounter outside a previously monogamous relationship, and a cystoscopy six weeks ago that raises enteric risk on its own. The third regimen is written for exactly his combination of organisms — but the parenthetical the CDC attaches to it names one specific enteric-risk population, men who practice insertive anal sex, and Marcus's enteric risk came from an instrument rather than from sex. He matches the regimen's microbiology without matching the population the guideline used to describe it, which is a narrower and more answerable question than the one the team thinks it is about to argue.
In urgent care, taking a careful history
A protected encounter three weeks ago sits right in the window for chlamydia or gonorrhea to cause exactly this. He's 36 — just past the traditional 35-year cutoff, though close enough to it that I'd still start ceftriaxone plus doxycycline and consider that sufficient.
I'd want levofloxacin in this regimen too. He had a cystoscopy six weeks ago, and instrumentation-associated epididymitis from enteric organisms is a real, recurring pattern independent of anything about his sexual history — the CDC's own 2021 framework names recent urologic instrumentation specifically as a reason to think enteric rather than defaulting to the STI pathway.
The age-based shortcut you're using is exactly what the 2021 update moved away from — it's an exposure-and-risk framework now, and he has a genuine enteric-risk exposure sitting right there in his history, not just an age that happens to sit near a traditional cutoff he's already past.
I don't think we need to choose — and I don't think we need three drugs to avoid choosing. The CDC already wrote the both-pathways regimen: for epididymitis judged likely to involve chlamydia, gonorrhea, and enteric organisms, it is ceftriaxone 500mg intramuscularly once plus levofloxacin 500mg daily for ten days. Note what that regimen does not contain: doxycycline. Levofloxacin covers chlamydia, so the guideline substitutes it rather than stacking both.
The one honest caveat: the CDC describes that regimen's enteric-risk group as men who practice insertive anal sex, and Marcus's enteric risk came from a cystoscope. I'd still use it — the organisms it targets are the organisms he is actually at risk for — but I want that said out loud rather than papered over, because it is the real gap in applying this regimen to him, and it is a much smaller gap than guessing which of his two exposures to ignore.
Agreed: treat empirically for both pathways using the CDC's own dual-risk regimen — ceftriaxone 500mg IM once plus levofloxacin 500mg daily for ten days — rather than selecting one exposure as more likely than the other, and rather than adding doxycycline on top of an agent that already covers chlamydia. De-escalation once NAAT and culture results return.
Not raised as an unresolved tension but worth naming: the emergency medicine physician's initial reliance on age as a rough guide was corrected in real time once the instrumentation history surfaced, not treated as a mistake so much as an example of exactly the shortcut the 2021 CDC update was written to move clinicians away from.